Association between microbial characteristics and poor outcomes among patients with methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study by Jennifer S. McDanel et al.
SHORT REPORT Open Access
Association between microbial
characteristics and poor outcomes among
patients with methicillin-resistant
Staphylococcus aureus pneumonia: a
retrospective cohort study
Jennifer S. McDanel1,2,3*, Eli N. Perencevich1,2,3, Daniel J. Diekema2,4,5, Patricia L. Winokur2,3, J. Kristie Johnson6,
Loreen A. Herwaldt1,2,5, Tara C. Smith1,8, Elizabeth A. Chrischilles1, Jeffrey D. Dawson7 and Marin L. Schweizer1,2,3
Abstract
Background: Methicillin-resistant S. aureus (MRSA) pneumonia is associated with poor clinical outcomes. This study
examined the association between microbial characteristics and poor outcomes among patients with methicillin-resistant
Staphylococcus aureus pneumonia.
Findings: This retrospective cohort study included 75 patients with MRSA pneumonia who were admitted to two large
tertiary care medical centers during 2003–2010. Multivariable models were created using Cox proportional hazards
regression and ordinal logistic regression to identify predictors of mortality or increased length of stay (LOS). None of the
microbial characteristics (PFGE type, agr dysfunction, SCCmec type, and detection of PVL, ACME, and TSST-1) were
significantly associated with 30-day mortality or post-infection hospital length of stay, after adjusting for gender, age,
previous hospital admission within 12 months, previous MRSA infection or colonization, positive influenza test, Charlson
Comorbidity Index score, and treatment (linezolid or vancomycin).
Conclusion: Large prospective studies are needed to examine the impact of microbial characteristics on the risk of death
and other adverse outcomes among patients with MRSA pneumonia.
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Findings
The literature is inconsistent regarding the association
between microbial characteristics and poor outcomes
among patients with methicillin-resistant Staphylococ-
cus aureus (MRSA) pneumonia. Prior studies have
linked the Panton-Valentine leukocidin (PVL) toxin
and accessory gene regulator (agr) locus with necrosis
of the lung [1, 2]. Additionally, some antimicrobials,
such as linezolid or clindamycin, used to treat MRSA
pneumonia may inhibit specific microbial virulence
mechanisms [3, 4]. This study evaluated a cohort of
patients with MRSA pneumonia to assess the associ-
ation between MRSA microbial characteristics and
poor outcomes such as death or increased hospital
length of stay (LOS).
This retrospective study included patients admitted to
the University of Iowa Hospitals and Clinics (UIHC) or
to the University of Maryland Medical Center (UMMC)
during 2003–2010. Patients were initially identified by
International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM) codes for influenza-
like illness [5] and were included if they had an ICD-9-
CM code for pneumonia (ICD-9-CM codes: 480–488,
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V12.61, 997.31), had a banked MRSA isolate from either
a respiratory or a blood culture during their admissions,
and began antibiotic therapy with vancomycin or linezo-
lid within 2 days before until fourteen days after the col-
lection of the first MRSA positive culture. This study
was approved by the institutional review board of the
University of Iowa.
Antimicrobial susceptibility testing was performed using
broth dilution as described by the Clinical and Laboratory
Standards Institute [6]. Isolates were tested for susceptibility
to tetracycline, trimethoprim-sulfamethoxazole, tigecycline,
levofloxacin, linezolid, daptomycin, and vancomycin. Het-
erogeneous vancomycin-intermediate S. aureus (hVISA)
screen testing was performed according to previously
published methods [7]. The methods for pulsed-field gel
electrophoresis (PFGE) are previously described, and a
similarity coefficient of 80 % determined genetic relatedness
[8, 9]. The agr screening test was performed by measuring
the expression of δ-hemolysin using a β-lysin disk [10].
Polymerase chain reaction testing was used to identify the
Panton-Valentine leukocidin (PVL) gene [9, 11], toxic shock
syndrome toxin-1 (TSST-1) gene [9, 12], arginine catabolic
mobile element (ACME) [9, 13], and staphylococcal cas-
sette chromosome mec (SCCmec) [9] types I to V.
The primary outcomes analyzed were 30-day all-
cause in-hospital mortality and post-infection hos-
pital LOS. Thirty-day mortality was defined as death
occurring within 30 days after the collection of the
Table 1 Unadjusted associations for mortality or post-infection length of stay among patients with MRSA pneumonia
Proportion of patients with
characteristic
30-Day-In-Hospital mortalitya Post-infection length of stayb
Characteristics Patients who
died N = 18
Patients who
survived N = 57
Hazards ratio (95 %
Confidence Interval)




Gender: Female 9 (50 %) 20 (35 %) 1.81 (0.72–4.57) 0.201 1.44 (0.63–3.30) 0.385
Age ≥55 years 4.69 (1.36–16.22) 0.015 2.15 (0.95–4.87) 0.068
Hospital admission within
previous 12 months
6 (33 %) 31 (54 %) 0.52 (0.19–1.37) 0.185 0.40 (0.17–0.91) 0.028
Previous MRSA infection or
colonization
6 (33 %) 11 (19 %) 1.82 (0.68–4.88) 0.234 1.31 (0.50–3.42) 0.583
Positive influenza test 2 (11 %) 3 (5 %) 1.69 (0.39–7.38) 0.488 2.13 (0.41–11.01) 0.368
Charlson comorbidity index
score- median (IQR)
2 (1–3) 2 (1–4) 0.99 (0.83–1.20) 0.948 0.99 (0.84–1.16) 0.896
Hospital-acquired infection 6 (33 %) 19 (33 %) 0.85 (0.32–2.29) 0.752 1.50 (0.64–3.53) 0.354
Antimicrobial prescribed
Linezolid 2 (11 %) 12 (21 %) 0.60 (0.14–2.60) 0.492 0.36 (0.13–1.03) 0.056
Vancomycin 17 (94 %) 54 (95 %) 0.61 (0.08–4.68) 0.223 3.10 (0.51–19.02) 0.221
Both linezolid and vancomycin 1 (6 %) 9 (16 %) 0.37 (0.05–2.76) 0.331 0.43 (0.13–1.41) 0.162
Microbial characteristics
Panton-Valentine leukocidin 5 (28 %) 24 (42 %) 0.82 (0.36–1.88) 0.645 0.82 (0.36–1.88) 0.645
SCCmec
Type II 12 (67 %) 27 (47 %) 1.22 (0.54–2.72) 0.634 1.22 (0.54–2.72) 0.634
Type IV 6 (33 %) 29 (51 %) 0.79 (0.35–1.76) 0.555 0.79 (0.35–1.76) 0.555
agr dysfunction 4 (22 %) 9 (16 %) 1.35 (0.44–4.10) 0.598 1.59 (0.54–4.62) 0.399
Arginine catabolic mobile
element
3 (17 %) 22 (39 %) 0.35 (0.10–1.20) 0.094 0.70 (0.30–1.64) 0.413
Toxic shock syndrome toxin-1 1 (6 %) 2 (4 %) 1.22 (0.16–9.19) 0.846 2.35 (0.29–19.27) 0.423
PFGE type
USA100 11 (61 %) 25 (44 %) 1.87 (0.72–4.82) 0.197 1.20 (0.54–2.69) 0.652
USA300 4 (22 %) 25 (44 %) 0.40 (0.13–1.21) 0.104 0.66 (0.29–1.51) 0.323
Other 3 (17 %) 7 (12 %) 1.40 (0.41–4.85) 0.594 1.57 (0.48–5.16) 0.458
IQR interquartile range, SCCmec staphylococcal cassette chromosome mec, agr accessory gene regulator, PFGE pulsed-field gel electrophoresis, hVISA
heterogeneous vancomycin-intermediate S. aureus
aDefined as death occurring within the first 30 days after the day when the first MRSA positive respiratory or blood culture was collected
bDefined as the day the first MRSA positive respiratory or blood culture was collected until the day the patient was either discharged from the hospital or died
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Table 2 Adjusted associations for mortality or post-infection length of stay among patients with MRSA pneumoniaa
30-Day-In-Hospital mortalityb Post-infection length of stayc
Microbial characteristics Hazards ratio (95 % Confidence Interval) P-value Odds ratio (95 % Confidence Interval) P-value
Panton-Valentine leukocidin 0.72 (0.23–2.25) 0.566 0.67 (0.27–1.69) 0.398
SCCmec
Type II 1.66 (0.53–5.16) 0.383 1.77 (0.69–4.52) 0.235
Type IV 0.62 (0.20–1.93) 0.414 0.51 (0.20–1.30) 0.158
agr dysfunction 1.84 (0.54–6.20) 0.323 1.30 (0.42–4.05) 0.648
Arginine catabolic mobile element 0.37 (0.10–1.47) 0.158 0.57 (0.22–1.48) 0.250
Toxic shock syndrome toxin-1 1.24 (0.14–11.10) 0.847 2.86 (0.26–31.18) 0.389
PFGE type
USA100 1.29 (0.42–3.95) 0.656 1.70 (0.67–4.33) 0.268
USA300 0.54 (0.15–1.92) 0.344 0.60 (0.24–1.50) 0.269
IQR interquartile range, SCCmec staphylococcal cassette chromosome mec, agr accessory gene regulator, PFGE pulsed-field gel electrophoresis
aAdjusted for gender, age, previous hospital admission within 12 months, previous MRSA infection or colonization, positive influenza test, Charlson Comorbidity
Index score, and treatment (linezolid or vancomycin)
bDefined as death occurring within the first 30 days after the day when the first MRSA positive respiratory or blood culture was collected
c Defined as the day the first MRSA positive respiratory or blood culture was collected until the day the patient was either discharged from the hospital or died
Table 3 Patient characteristics, microbial characteristics, or treatments associated with strain type (N = 65)
Characteristics USA100 N = 36 USA300 N = 29 P-value
Patient characteristics
Gender: Female 16 (44 %) 9 (31 %) 0.269
Age ≥55 years 24 (67 %) 11 (38 %) 0.021
Hospital admission within previous 12 months 21 (58 %) 11 (38 %) 0.102
Hospital-acquired infection 10 (28 %) 12 (41 %) 0.249
Previous MRSA infection or colonization 8 (22 %) 5 (17 %) 0.618
Positive influenza test 1 (3 %) 2 (7 %) 0.582
Post-infection length of stay: median (IQR), in daysa 6 (2–18) 12 (4–24) 0.232
Charlson Comorbidity Index score: median (IQR) 2 (1–3) 2 (0–4) 0.778
30-day mortalityb 11 (31 %) 4 (14 %) 0.111
Antimicrobial prescribed
Linezolid 11 (31 %) 2 (7 %) 0.018
Vancomycin 33 (92 %) 29 (100 %) 0.247
Microbial characteristics
agr dysfunction 8 (22 %) 4 (14 %) 0.384
Toxic shock syndrome toxin-1 1 (3 %) 0 (0 %) 1.000
hVISA 1 (3 %) 0 (0 %) 1.000
Arginine catabolic mobile element 1 (3 %) 23 (79 %) <0.001
Panton-Valentine leukocidin 0 (0 %) 26 (90 %) <0.001
SCCmec
Type II 35 (97 %) 4 (14 %) <0.001
Type IV 0 (0 %) 25 (86 %) <0.001
IQR interquartile range, SCCmec staphylococcal cassette chromosome mec, agr accessory gene regulator, PFGE pulsed-field gel electrophoresis, hVISA
heterogeneous vancomycin-intermediate S. aureus
aDefined as the day the first respiratory or blood culture that grew MRSA was collected until the day the patient was either discharged from the hospital or died
bDefined as death occurring within the first 30 days after the day when the first respiratory or blood culture that grew MRSA was obtained
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first MRSA positive respiratory or blood culture. Hos-
pital LOS was measured beginning on the day the
first MRSA positive respiratory or blood culture was
collected until either hospital discharge or death. Co-
morbidities were measured using the Charlson Co-
morbidity Index [14]. Age was dichotomized on the
median. Information was collected on hospital admis-
sion within the previous 12 months, previous MRSA
infection or colonization, and having a positive influ-
enza test during hospital admission. Hospital-acquired
infections were defined as the first MRSA positive re-
spiratory or blood culture collected more than 2 days
after hospital admission.
Bivariable analyses were conducted using either Stu-
dent’s t-test or the Wilcoxon Rank Sum test for continu-
ous variables and either the chi-square test or Fisher’s
exact test for categorical variables. Cox proportional
hazard regression and ordinal logistic regression were
used to perform the multivariable analyses assessing the
association between microbial factors and 30-day mor-
tality or LOS. Patients who did not die were categorized
based on their length of stay: 0–3 days, 4–10 days, 11–20
days, and ≥21 days. Deceased patients were placed in a
separate category since they had the worst outcome and
varying lengths of stay before death. Variables with
P<0.25 in the bivariable analysis were entered into the
model using a manual stepwise method, and remained
in the multivariable model if they were statistically sig-
nificant (P<0.05). Data were analyzed using SAS soft-
ware (SAS Institute, Cary, NC) version 9.3.
The cohort was comprised of 75 patients with MRSA
pneumonia. The majority of patients were male (61 %)
and the median age was 54. Twenty-four percent (18/75)
of the patients died and the median post-infection LOS
in the hospital was 9 days (interquartile range: 3–20).
Most isolates were from respiratory cultures, including
bronchial washes (9 %), tracheal aspirates (7 %), and
sputum cultures (83 %).
Patients who survived were more likely than pa-
tients who died to be infected with MRSA isolates
that were PVL-positive (42 % vs. 28 %; P = 0.277) or
ACME-positive (39 % vs. 17 %; P = 0.085). Patients
who died were more likely than those who survived
to be infected with MRSA isolates with a dysfunc-
tional agr (22 % vs. 16 %; P = 0.530). However, none
of these results reached statistical significance
(Table 1). Most MRSA isolates were susceptible to
all antimicrobials tested except levofloxacin (9 %
susceptible). All isolates were susceptible to vanco-
mycin [minimum inhibitory concentration (MIC)
range: 0.5–1 μg/mL] and linezolid (MIC range: 0.5–2
μg/mL) [Additional file: Susceptibility to antimicrobial
agents of MRSA isolates from patients with MRSA
pneumonia (N = 75) (see Additional file 1)]. None of
the microbial characteristics were statistically signifi-
cantly associated with increased post-infection LOS or
mortality in the multivariable analyses statistically
adjusting for gender, age, previous hospital admission
within 12 months, previous MRSA infection or
colonization, positive influenza test, Charlson Co-
morbidity Index score, and treatment (linezolid or
vancomycin) (Table 2).
Sixty-five patients (87 %) were infected with either a
USA300 strain or a USA100 strain. Patients infected
with a USA300 strain were less likely to receive linezolid
(7 % vs. 31 %; P = 0.018) and were more likely to be
younger (<55 years) [38 % vs. 67 %; P = 0.021] compared
with patients infected with a USA100 strain (Table 3).
Additionally, 14 % of the patients infected with a
USA300 strain died compared with 31 % of the patients
infected with a USA100 strain (P = 0.111).
Numerous investigators have tried to determine
whether specific microbial characteristics of MRSA in-
fecting isolates are associated with poor outcomes [1, 2,
15, 16]. However, the results of those studies vary sub-
stantially. Even though this study was larger than most
studies to examine microbial characteristics associated
with MRSA pneumonia, this study did not identify any
statistically significant associations between the micro-
bial characteristics and outcomes. Even though the risk
estimates suggested an association between a few of the
microbial characteristics and death or increased post-
infection LOS, the confidence intervals were wide, po-
tentially due to the limited sample size and small num-
ber of patients who died. However, among patients
infected with USA100 strains or USA300 strains, there
was a trend toward increased mortality among those in-
fected with USA100 strains.
Our study had limitations. First, patients might
have been colonized in the throat or upper respira-
tory tract rather than having MRSA respiratory in-
fections. To identify MRSA infected patients, this
study only included patients who received vanco-
mycin or linezolid (agents active against MRSA).
Second, influenza-like illness ICD-9-CM codes were
used to identify the study population because the pa-
tients initially were included in a study of influenza-
like illness and MRSA pneumonia, thus this cohort
may be subject to selection bias. However, this is
not a large concern since cough was the most com-
mon influenza-like illness code identified. Finally,
since this is a retrospective study, patients who had
pneumonia but did not have a culture collected dur-
ing their admission would not be included in the
study. Large prospective studies are needed to assess
whether microbial factors in combination with treat-
ment factors or patient factors increase the risk of
death and other adverse outcomes.
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Additional file
Additional file 1. Susceptibility to antimicrobial agents of MRSA
isolates from patients with MRSA pneumonia (N = 75). The
susceptibility results for the 75 isolates that were tested to tetracycline,
trimethoprim-sulfamethoxazole, tigecycline, levofloxacin, linezolid, dapto-
mycin, and vancomycin. (DOCX 14 kb)
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